NASDAQ:XLRNAcceleron Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acceleron Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $92.20 -0.68 (-0.73 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$91.45Now: $92.20▼$94.0950-Day Range$92.20MA: $100.93▼$110.2552-Week Range$37.60Now: $92.20▼$110.75Volume353,000 shsAverage Volume680,413 shsMarket Capitalization$5.52 billionP/E RatioN/ADividend YieldN/ABeta0.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingAcceleron Pharma has received a consensus rating of Buy. The company's average rating score is 2.77, and is based on 11 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $117.92, Acceleron Pharma has a potential upside of 27.9% from its current price of $92.20.Amount of Analyst CoverageAcceleron Pharma has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesAcceleron Pharma has received 539 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcceleron Pharma has received 373 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcceleron Pharma has received 59.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote “Outperform” if you believe XLRN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcceleron Pharma does not currently pay a dividend.Dividend GrowthAcceleron Pharma does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acceleron Pharma insiders have bought 98.03% more of their company's stock than they have sold. Specifically, they have bought $9,999,990.00 in company stock and sold $5,049,709.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Acceleron Pharma is held by insiders.Percentage Held by Institutions88.77% of the stock of Acceleron Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acceleron Pharma are expected to decrease in the coming year, from ($3.04) to ($3.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acceleron Pharma is -35.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acceleron Pharma is -35.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcceleron Pharma has a P/B Ratio of 10.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.28 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XLRN Previous Symbol CUSIPN/A CIK1280600 Webwww.acceleronpharma.com Phone617-649-9200Debt Debt-to-Equity Ratio0.04 Current Ratio15.15 Quick Ratio15.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$73.99 million Price / Sales74.64 Cash FlowN/A Price / Cash FlowN/A Book Value$8.47 per share Price / Book10.89Profitability EPS (Most Recent Fiscal Year)($2.38) Net Income$-124,860,000.00 Net Margins-157.84% Return on Equity-31.25% Return on Assets-27.88%Miscellaneous Employees173 Outstanding Shares59,897,000Market Cap$5.52 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $92.20 -0.68 (-0.73 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive XLRN News and Ratings via Email Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter. Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions How has Acceleron Pharma's stock been impacted by Coronavirus? Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XLRN shares have increased by 9.3% and is now trading at $92.20. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Acceleron Pharma? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 1 sell rating, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Acceleron Pharma. When is Acceleron Pharma's next earnings date? Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Acceleron Pharma. How were Acceleron Pharma's earnings last quarter? Acceleron Pharma Inc (NASDAQ:XLRN) announced its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.21. The biopharmaceutical company earned $39.75 million during the quarter, compared to analysts' expectations of $30.08 million. Acceleron Pharma had a negative net margin of 157.84% and a negative return on equity of 31.25%. The company's revenue for the quarter was up 43.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.34) earnings per share. View Acceleron Pharma's earnings history. What price target have analysts set for XLRN? 13 brokerages have issued 12 month target prices for Acceleron Pharma's shares. Their forecasts range from $71.00 to $140.00. On average, they anticipate Acceleron Pharma's stock price to reach $117.92 in the next year. This suggests a possible upside of 27.9% from the stock's current price. View analysts' price targets for Acceleron Pharma. What are Wall Street analysts saying about Acceleron Pharma stock? Here are some recent quotes from research analysts about Acceleron Pharma stock: 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (1/16/2020) 2. HC Wainwright analysts commented, "We are lowering our price target to $68 from $69 due to the discontinuation of ACE-083 for FSHD. Our $68 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline, and estimated year-end cash." (9/17/2019) Has Acceleron Pharma been receiving favorable news coverage? News stories about XLRN stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acceleron Pharma earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Acceleron Pharma. Are investors shorting Acceleron Pharma? Acceleron Pharma saw a decrease in short interest in July. As of July 31st, there was short interest totaling 3,120,000 shares, a decrease of 6.9% from the July 15th total of 3,350,000 shares. Based on an average daily volume of 692,400 shares, the short-interest ratio is presently 4.5 days. Currently, 6.2% of the shares of the stock are short sold. View Acceleron Pharma's Short Interest. Who are some of Acceleron Pharma's key competitors? Some companies that are related to Acceleron Pharma include NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Qiagen (QGEN), argenx (ARGX), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Novavax (NVAX), Repligen (RGEN), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), bluebird bio (BLUE), Iovance Biotherapeutics (IOVA) and China Biologic Products (CBPO). View all competitors. What other stocks do shareholders of Acceleron Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Pfizer (PFE), AbbVie (ABBV), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Exelixis (EXEL). Who are Acceleron Pharma's key executives? Acceleron Pharma's management team includes the following people: Mr. Habib J. Dable, CEO, Pres & Director (Age 50)Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48) What is Acceleron Pharma's stock symbol? Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN." Who are Acceleron Pharma's major shareholders? Acceleron Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (12.82%), TimesSquare Capital Management LLC (1.81%), Goldman Sachs Group Inc. (0.82%), Candriam Luxembourg S.C.A. (0.71%), Bank of New York Mellon Corp (0.55%) and New York State Common Retirement Fund (0.44%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View institutional ownership trends for Acceleron Pharma. Which major investors are selling Acceleron Pharma stock? XLRN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Candriam Luxembourg S.C.A., State of Wisconsin Investment Board, Goldman Sachs Group Inc., Prudential Financial Inc., UBS Group AG, SG Americas Securities LLC, and Bank of New York Mellon Corp. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Corp /De/ Celgene, Habib J Dable, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar, and Sujay Kango. View insider buying and selling activity for Acceleron Pharma. Which major investors are buying Acceleron Pharma stock? XLRN stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., New York State Common Retirement Fund, Rhenman & Partners Asset Management AB, Sofinnova Investments Inc., Principal Financial Group Inc., State Board of Administration of Florida Retirement System, WINTON GROUP Ltd, and Virtu Financial LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene, and Joseph S Zakrzewski. View insider buying and selling activity for Acceleron Pharma. How do I buy shares of Acceleron Pharma? Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Acceleron Pharma's stock price today? One share of XLRN stock can currently be purchased for approximately $92.20. How big of a company is Acceleron Pharma? Acceleron Pharma has a market capitalization of $5.52 billion and generates $73.99 million in revenue each year. The biopharmaceutical company earns $-124,860,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe. What is Acceleron Pharma's official website? The official website for Acceleron Pharma is www.acceleronpharma.com. How can I contact Acceleron Pharma? Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
